Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
Authors:
- Stefano CavalieriSCStefano Cavalieri
- Daria Maria FilippiniDFDaria Maria Filippini
- Arianna OttiniAOArianna Ottini
- Cristiana BergaminiCBCristiana Bergamini
- Carlo ResteghiniCRCarlo Resteghini
- Elena ColomboECElena Colombo
- Roberta LombardoRLRoberta Lombardo
- Salvatore AlfieriSASalvatore Alfieri
- Lisa LicitraLLLisa Licitra
- Laura D. LocatiLLLaura D. Locati
Open Access
- 31 December 2021
- journal article
- review article
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 2 (6) , 522-542
Abstract
The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In recent years, the deeper and increasing knowledge on the genomic landscape and the upcoming new data on immunotherapy enacted by HNSCCs have led to successful therapeutic targeting of the immune system. Immune checkpoint inhibitors (ICIs) have changed state of the art in R/M patients and could have a potential role even in early disease. The purpose of this work is to summarize the role of immunotherapy for R/M HNSCC in clinical practice, with insights about future perspectives. Updated immunotherapy results in other R/M head and neck cancers such as thyroid, salivary glands, nasopharynx, sinonasal cancers, and nuclear protein in testis (NUT) are presented.Keywords
This publication has 109 references indexed in Scilit:
- PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck CancerCancer Research, 2013
- Pathologic Characteristics of NUT Midline Carcinoma Arising in the MediastinumAmerican Journal of Surgical Pathology, 2012
- T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical resultsAnnals of Oncology, 2011
- Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial NeoplasiaNew England Journal of Medicine, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- NUT Rearrangement in Undifferentiated Carcinomas of the Upper Aerodigestive TractAmerican Journal of Surgical Pathology, 2008
- Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group StudyYearbook of Oncology, 2007
- Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T LymphocytesJournal of Clinical Oncology, 2005
- Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2005
- Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytesBlood, 2005